Trial Profile
Open-Label, 40-weeks Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs MCS 2 (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions
- Sponsors Health Ever Bio-Tech
- 27 Nov 2015 According to a Health Ever Bio Tech media release, it the only Taiwanese biotechnology company to receive US FDA Botanical New Drug IND approval for conducting Phase III clinical trials.
- 27 Nov 2015 New trial record